Angioedema
MONDO:0010481Swelling involving the deep dermis, subcutaneous, or submucosal tissues, representing localized edema. Angioedema often occurs in the face, lips, tongue, and larynx.
Also known as: Edemas, angioneurotic, Quincke edema, Quincke oedema, Quincke's edema, Quincke's oedema, Quinckes edema, Quinckes oedema, Urticarias, giant
67 clinical trials for this condition and its sub-types, 19 tagged with Angioedema itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Angioedema
-
Hereditary angioedema 58 trials · 60 incl. sub-types
10 sub-types
- Hereditary angioedema with C1Inh deficiency 14 trials · 32 incl. sub-types Sub-types →
- Hereditary angioedema type 3 2 trials
- Hereditary angioedema with normal C1Inh 2 trials
- PLG-related hereditary angioedema with normal C1inh 0 trials
- Angioedema, hereditary, 4 0 trials
- Angioedema, hereditary, 5 0 trials
- Angioedema, hereditary, 6 0 trials
- Angioedema, hereditary, 7 0 trials
- Angioedema, hereditary, 8 0 trials
- Hereditary angioedema with normal C1inh not related to F12 or PLG variant 0 trials
-
Acquired angioedema 2 trials · 3 incl. sub-types
5 sub-types
- Renin-angiotensin-aldosterone system-blocker-induced angioedema 2 trials
- Acquired angioedema with C1Inh deficiency 1 trial
- Acquired angioedema type 1 0 trials
- Acquired angioedema type 2 0 trials
- Vibratory angioedema 0 trials
-
Non-histaminic angioedema 2 trials
Most studied deeper sub-types
-
New pill could stop and treat dangerous swelling attacks
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called deucrictibant in adults with acquired angioedema due to C1 inhibitor deficiency, a rare condition causing sudden, painful swelling attacks. The study has three parts: one to see if a daily extended-release tablet can prevent attacks, a…
Phase 3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Sep 21, 2026 16:00 UTC
-
New daily pill could stop debilitating swelling attacks in HAE patients
Disease control Recruiting nowThis Phase 3 study tests a once-daily pill called deucrictibant to prevent swelling attacks in people aged 12 and older with hereditary angioedema (HAE). The trial will enroll 170 participants and monitor safety and attack rates over a long period. Unlike a cure, patients would n…
Phase 3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New oral option may offer relief for hereditary angioedema attacks
Disease control Expanded accessThis program provides access to an experimental oral medication called deucrictibant for people with hereditary angioedema (HAE) who have no satisfactory alternative treatments for acute attacks. Eligible participants, aged 12 to 75, take the capsule as needed to manage swelling …
Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug aims to stop swelling attacks in hereditary angioedema
Disease control Recruiting nowThis phase 3 study tests an intravenous C1 esterase inhibitor (C1-INH) in people with hereditary angioedema (HAE) to treat acute attacks and prevent attacks before medical procedures. About 124 participants, aged 2 and older, will receive either the drug or a placebo. The main go…
Phase 3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New HAE drug garadacimab tested in real life: will it hold up?
Disease control Recruiting nowThis study follows 200 people with hereditary angioedema (HAE) who are starting garadacimab in routine medical care. Researchers will track how well the drug prevents swelling attacks, its safety, and its impact on quality of life over 48 months. The goal is to see if results fro…
Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Blood test revolution: pinpointing the cause of swelling attacks
Diagnosis Recruiting nowThis study evaluates whether new blood tests can more accurately diagnose the cause of recurrent angioedema—a condition causing severe swelling—compared to current tests. Researchers will compare novel diagnostic assays with traditional ones in 600 people aged 12 and older who ha…
Sponsor: Foundation For Rare Disease Research • Aim: Diagnosis
Last updated Aug 26, 2026 00:00 UTC
-
Can a national biobank network end the diagnostic odyssey for rare diseases?
Knowledge-focused Recruiting nowThis study aims to create a network of biobanks across Italy that collect and store biological samples and health data from people with rare diseases and their families. The goal is to standardize how samples are collected and shared, so researchers can access high-quality materi…
Sponsor: IRCCS Policlinico S. Donato • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Massive biobank launches to unlock secrets of chronic inflammation
Knowledge-focused Recruiting nowThis study is building a large database and biobank from 2200 people with chronic inflammatory diseases like lupus, multiple sclerosis, severe asthma, and psoriasis. Researchers will collect blood samples and track disease activity over time using standard medical scores. The goa…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Massive study seeks genetic roots of allergies and immune problems
Knowledge-focused Recruiting nowThis study aims to find the genetic causes behind certain allergic and immune system disorders. Researchers will collect blood, saliva, and tissue samples from up to 10,000 people of all ages, along with some family members. No treatments are given; the goal is simply to learn mo…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC